Milligest (Ethinylestradiol, Gestodene)

Ethinylestradiol and Gestodene, the active ingredients in Milligest, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering the endometrium.

GNH USA supplies Milligest as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milligest is a combined hormonal contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy. - Contraception: Prevents pregnancy by suppressing ovulation and altering cervical mucus. - Menstrual cycle regulation: Provides more predictable menstrual bleeding patterns. - Acne improvement: May reduce acne associated with androgen excess.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: transient cranial pain. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new or worsening high blood pressure. - Liver dysfunction: jaundice or hepatic enzyme elevation. - Gallbladder disease: cholelithiasis or biliary colic. - Severe allergic reaction: anaphylaxis or angioedema.

Before initiating Milligest, consider the following precautions. - Assess thromboembolic risk: evaluate personal and family history of clotting disorders. - Avoid smoking: especially in women over 35 years of age. - Monitor blood pressure: check regularly for hypertension. - Review hepatic function: contraindicated in severe liver disease. - Check medication history: avoid concomitant use with strong enzyme inducers. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Milligest may interact with several medicines. Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy. - Rifampicin or griseofulvin: may decrease hormonal levels. - Protease inhibitors (e.g., ritonavir): increase risk of adverse effects. - St. John’s wort: may lower contraceptive effectiveness. Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may raise hormone concentrations. - SSRIs (e.g., fluoxetine): could enhance mood‑related side effects. - Diuretics: may affect fluid balance and blood pressure.